Individualizing Treatment for Patients with Myasthenia Gravis

This module explores how to individualize treatment for MG by evaluating response to standard therapies and identifying patients who may benefit from targeted therapeutic options. Learn how to tailor care based on antibody subtype, disease severity, and patient needs.
Dr. Joshua P. Alpers, MD

Neurologist; Director, Certified Electrodiagnostic Laboratory
Erlanger Neurology/Erlanger Medical Center
Chattanooga, TN

Dr. Joshua P. Alpers, MD, is a board-certified neurologist specializing in neuromuscular medicine and electrodiagnostic testing at Erlanger Neurology in Chattanooga, Tennessee. He serves as the director of the region's only certified electrodiagnostic laboratory and holds the position of Affiliated Assistant Professor in the Department of Neurology at the University of Tennessee Health Science Center.

Dr. Alpers earned his medical degree from the University of Missouri School of Medicine. He completed his internship in Internal Medicine and residency in Neurology at Wilford Hall Medical Center/Lackland Air Force Base, where he served as Chief Resident. Following this, he pursued a fellowship in Neuromuscular Medicine at Duke University Medical Center.

Prior to his current roles, Dr. Alpers was Chief of Neurophysiology at Wright-Patterson Medical Center and held teaching positions at Wright State School of Medicine and the Uniformed Services University of Health Sciences. His clinical interests include disorders of the neuromuscular junction, such as myasthenia gravis, and advanced diagnostic techniques like single-fiber electromyography and peripheral nerve ultrasonography.

1.
EVALUATE patient response to standard treatment to develop individualized care plans
2.
DIFFERENTIATE patients who would benefit from more targeted therapies at early stages or after developing refractory disease